

16524
Sfw

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on June 18, 2004.

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

COMMUNICATION
Examining Group 1652
Patent Application
Docket No. G-078US04CIP
Serial No. 09/876,997

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Delia M. Ramirez
Art Unit : 1652
Applicants : Jean-Baptiste Dumas Milne Edwards, Lydie Bougueleret, Severin Jobert
Serial No. : 09/876,997
Filed : June 8, 2001
Conf. No. : 2239
For : Full-length Human cDNAs Encoding Potentially Secreted Proteins

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

COMMUNICATION


Sirs:

In response to the Interview Summary of June 17, 2004, enclosed are true and correct copies of the following documents which were mailed to the U.S. Patent Office on December 22, 2003:

1. Amendment Under 37 C.F.R. § 1.111
2. Petition and Fee for Extension of Time Under 37 CFR §1.136(a)
3. Declaration of Frank C. Eisenschenk, Ph.D.
4. Second Supplemental Information Disclosure Statement Under 37 CFR §§1.97 and 1.98
5. Copies of references cited in Information Disclosure Statement.

Also enclosed is a copy of the return postcard evidencing receipt of the above documents by the Patent Office. Applicants would also like to thank the Examiner for the courtesy of the telephonic conference conducted with Applicants' undersigned representative on June 17, 2004. As indicated in the Interview Summary, a discussion as to the filing of the response to the outstanding Office Action dated August 21, 2003 in this matter was undertaken. Pursuant to the Examiner's request, a duplicate copy of the response (including a copy of the return postcard date stamped by the Patent Office on December 29, 2003) apparently misplaced by the Patent Office is transmitted herewith.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/sl

Enclosures:

1. Amendment Under 37 C.F.R. § 1.111
2. Petition and Fee for Extension of Time Under 37 CFR §1.136(a)
3. Declaration of Frank C. Eisenschenk, Ph.D.
4. Second Supplemental Information Disclosure Statement Under 37 CFR §§1.97 and 1.98
5. Copies of references cited in Information Disclosure Statement.

Transaction List

Search by

☐ Accounting Date: Operator ID:

(MMDDYY)

Accounting Date

Starts:

Ends:

☒ Name/Number:

☐ Attny Docket No:

☐ Deposit Account No.:



Accounting Date	Operator ID	Seq. No.	Txn Src	Fee Code	St	Amount	Name/Number	Dep Acct
01/06/2004	HALI11	5	SALE	1806	A	180.00	09876997	190065
01/06/2004	HALI11	4	SALE	2251	A	55.00	09876997	190065
08/28/2003	RAMPTAS	49	SALE	8021	A	40.00	09876997	190065
12/05/2001	DBYRNE	36	SALE	581	A	40.00	09876997	
12/04/2001	BABRAHA1	49	SALE	205	A	65.00	09876997	
06/13/2001	NROCHA1	17	SALE	103	A	36.00	09876997	
06/13/2001	NROCHA1	16	SALE	101	A	710.00	09876997	




Adjustment Detail

Authorization Detail





12/22/03




DOCKET NO.: G-078US04CIP

JAN - 2 2004

APPLICANTS: Dumas Milne Edwards et al

SERIAL NO.: 09/876,997

FILED : June '8, 2001



SUBMISSION TO PTO:

- 1) Petition and Fee for Extension of Time Under 37 CFR §1.136(a) (in triplicate)
- 2) Declaration (deposit under Budapest Treaty)
- 3) Amendment Under 37 C.F.R. §1.111
- 4) Second Supplemental Information Disclosure Statement Under 37 CFR §§1.97 and 1.98

/s1



PF

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on December 22, 2003

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Examining Group 1652

Patent Application

Docket No. G-078US04CIP

Serial No. 09/876,997

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Delia M. Ramirez
Art Unit : 1652
Applicants : Jean-Baptiste Dumas Milne Edwards, Lydie Bougueleret, Severin Joubert
Serial No. : 09/876,997
Filed : June 8, 2001
Conf. No. : 2239
For : Full-length Human cDNAs Encoding Potentially Secreted Proteins

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:


In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/dkt

Attachments: Form PTO/SB/08; copies of references cited therein.



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on December 22, 2003.

Frank C. Eisenschenk, Ph.D., Patent Attorney

PETITION AND FEE FOR EXTENSION OF TIME UNDER 37 CFR §1.136(a)

Examining Group 1652

Patent Application

Docket No. G-078US04CIP

Serial No. 09/876,997

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Delia M. Ramirez
Art Unit : 1652
Applicants : Jean-Baptiste Dumas Milne Edwards, Lydie Bougueleret, Severin Joubert
Serial No. : 09/876,997
Filed : June 8, 2001
Conf. No. : 2239
For : Full-length Human cDNAs Encoding Potentially Secreted Proteins

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313

PETITION AND FEE FOR EXTENSION OF TIME
UNDER 37 CFR §1.136(a)

Sir:

Applicants request that the period for response be extended one month through and including December 22, 2003. An Amendment Under 37 CFR §1.111 accompanies this Petition. Please charge the fee of \$55.00 to Deposit Account No. 19-0065.

Any additional fees as required by 37 CFR §§1.16 or 1.17 should be charged to Deposit Account No. 19-0065. Two additional copies of this Petition are enclosed.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRP/sl

Attachment: Amendment Under 37 C.F.R. §1.111



PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/876,997
				Filing Date	June 8, 2001
				First Named Inventor	Jean-Baptiste Dumas Milne Edwards
				Art Unit	1652
				Examiner Name	Delia M. Ramirez
Sheet	1	of	3	Attorney Docket Number	G-078US04CIP

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-5,019,369	05/28/1991	Presant <i>et al.</i>	
	U2	US-5,872,141	02/16/1999	Umbreit <i>et al.</i>	
	U3	US-6,034,062	03/07/2000	Thies <i>et al.</i>	
	U4	US-6,204,060	03/20/2001	Mehtali <i>et al.</i>	
	U5	US-6,110,490	08/29/2000	Thierry	
	U6	US-6,242,179	06/05/2001	Shah <i>et al.</i>	
	U7	US-			
	U8	US-			
	U9	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)			
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	09/876,997
Filing Date	June 8, 2001
First Named Inventor	Jean-Baptiste Dumas Milne Edwards
Group Art Unit	1652
Examiner Name	Delia M. Ramirez
Attorney Docket Number	G-078US04CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ABRAHAM, E., <i>et al.</i> , "Phosphatidic Acid Signaling Mediates Lung Cytokine Expression and Lung Inflammatory Injury After Hemorrhage in Mice", <i>J. Exp. Med.</i> , 1995, pages 569-575, Volume 181.	
	R2	BRINDLEY, D. and WAGGONER, D. "Phosphatidate phosphohydrolase and signal transduction", <i>Chem. Phys. Lipids</i> , 1996, pages 45-57, Volume 80.	
	R3	BURSTEN, S., <i>et al.</i> , "Potential Role for Phosphatidic Acid in Mediating the Inflammatory Responses to TNF α and IL-1 β ", <i>Circ. Shock</i> , 1994, pages 14-29, Volume 44.	
	R4	ENGLISH, D., "Phosphatidic Acid: A Lipid Messenger Involved in Intracellular and Extracellular Signalling", <i>Cell. Signal.</i> , 1996, pages 341-347, Volume 8, No. 5.	
	R5	ENGLISH, D., <i>et al.</i> , "Messenger functions of phosphatidic acid", <i>Chem. Phys. Lipids</i> , 1996, pages 117-132, Volume 80.	
	R6	KENT, C. "Eukaryotic Phospholipid Biosynthesis", <i>Ann. Rev. Biochem.</i> , 1995, pages 315-343, Volume 64.	
	R7	LEUNG, D., <i>et al.</i> , "CT-2576, an inhibitor of phospholipids signaling, suppresses constitutive and induced expression of human immunodeficiency virus", <i>Proc. Natl. Acad. Sci. USA</i> , 1995, pages 4813-4817, Volume 92.	
	R8	RICE, G., <i>et al.</i> , "Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid", <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 3857-3861, Volume 91.	
	R9	ROBERTS, R. and MORRIS, A. "Role of phosphatidic acid phosphatase 2a in uptake of extracellular lipid phosphate mediators", <i>Biochimica et Biophysica Acta</i> , 2000, pages 33-49, Volume 1487.	
	R10	SALVADOR, G.A., <i>et al.</i> , "Differential modulation of phospholipase D and phosphatidate phosphohydrolase during aging in rat cerebral cortex synaptosomes", <i>Exp. Gerontology</i> , 2002, pages 543-552, Volume 37.	
	R11	STUKEY, J. and CARMAN, G. "Identification of a novel phosphatase sequence motif", <i>Protein Science</i> , 1997, pages 469-472, Volume 6.	
	R12	Database GENBANK, Accession NP_003702; PANDEY, A.V., <i>et al.</i> , "Protein phosphatase 2A and phosphoprotein SET regulate androgen production by p450c17", <i>J. Biol. Chem.</i> , 2003, pages 2837-2844, Volume 278, Issue 5.	
	R13	Database GENBANK, Accession No. NP_795714; PANDEY, A.V., <i>et al.</i> , "Protein phosphatase 2A and phosphoprotein SET regulate androgen production by p450c17", <i>J. Biol. Chem.</i> , 2003, pages 2837-2844, Volume 278, Issue 5.	

Examiner
Signature

Date


Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/876,997	
			Filing Date	June 8, 2001	
			First Named Inventor	Jean-Baptiste Dumas Milne Edwards	
			Group Art Unit	1652	
			Examiner Name	Delia M. Ramirez	
Sheet	3	of	3	Attorney Docket Number	G-078US04CIP

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R14	Database GENBANK, Accession No. NP_803133; ISHIKAWA, T., <i>et al.</i> , "Cell surface activities of the human type 2b phosphatidic acid phosphatase", <i>J. Biochem.</i> , 2000, pages 645-651, Volume 127, Issue 4.		
	R15	Database GENBANK, Accession No. NP_808211; ZHANG, N., <i>et al.</i> , "Mice mutant for Ppap2c, a homolog of the germ cell migration regulator wunen, are viable and fertile", <i>Genesis</i> , 2000, pages 137-140, Volume 27, Issue 4.		
	R16	Accession No. AAB70690, Human hDPP protein sequence SEQ ID NO:7, May 17, 2001.		
	R17	JACOBS, K. <i>et al.</i> "A Novel Method for Isolating Eukaryotic cDNA Clones Encoding Secreted Proteins", <i>Dendritic Cells: Antigen Presenting Cells of T and B Lymphocytes</i> , March 10-16, 1995, page C1-207.		
	R18			
	R19			
	R20			
	R21			
	R22			
	R23			
	R24			
	R25			
	R26			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.